Amama E A, Taga M, Minaguchi H
Department of Obstetrics and Gynecology, Yokohama City University School of Medicine, Japan.
J Clin Endocrinol Metab. 1998 Feb;83(2):333-8. doi: 10.1210/jcem.83.2.4565.
To evaluate the clinical utility of recently developed biochemical markers in the assessment of bone metabolism during GnRH agonist (GnRHa) treatment, we compared five bone resorption markers [C-telopeptide (CTX) and N-telopeptide (NTX) of type I collagen, hydroxyproline (Hpr), pyridinoline (Pyr), and deoxypyridinoline (Dpyr)] and two bone formation markers [total alkaline phosphatase (Alp) and osteocalcin (OC)]. Sixty-eight normally menstruating women were injected with a long-acting GnRHa once a month for 24 weeks for the treatment of endometriosis or leiomyoma. The mean percentage bone loss at the lumbar spine was 3.79% at the end of treatment. Although levels of all markers increased significantly as the treatment progressed, CTX and NTX exhibited the highest correlation coefficients between bone loss at 24 weeks and the seven markers measured at 0, 4, 12, 16, and 24 weeks of treatment. Serum estradiol levels were similarly suppressed during the treatment in both fast losers (whose bone loss was more than the mean) and slow losers (whose bone loss was less than the mean). However, significantly higher z-scores of bone resorption markers, but not of bone formation markers, were observed in the fast losers at 24 weeks of treatment, suggesting a more accelerated bone resorption in this group. Whereas the three highest z-scores at 24 weeks of treatment were CTX, NTX, and Dpyr (in that order), the highest z-score (P < 0.05) was observed for CTX in the fast losers. The subjects in the highest quartile of CTX, the highest, and second highest quartiles of NTX at 24 weeks of treatment experienced 2.1, 2.2, and 1.7 times more bone loss (P < 0.001), respectively, than those in the lowest quartiles. Furthermore, the subjects in the highest quartile of both CTX and NTX experienced 3.6 times more bone loss (P < 0.001) than those in the lowest quartile of both markers. These results indicate that both CTX and NTX are useful and sensitive markers for bone resorption in a hypoestrogenic state induced by GnRHa.
为评估近期开发的生化标志物在促性腺激素释放激素激动剂(GnRHa)治疗期间骨代谢评估中的临床效用,我们比较了五种骨吸收标志物[I型胶原C端肽(CTX)和N端肽(NTX)、羟脯氨酸(Hpr)、吡啶啉(Pyr)和脱氧吡啶啉(Dpyr)]以及两种骨形成标志物[总碱性磷酸酶(Alp)和骨钙素(OC)]。68名月经正常的女性每月注射一次长效GnRHa,共治疗24周,用于治疗子宫内膜异位症或平滑肌瘤。治疗结束时,腰椎的平均骨丢失率为3.79%。尽管随着治疗进展,所有标志物水平均显著升高,但CTX和NTX在24周时的骨丢失与治疗0、4、12、16和24周时测量的七种标志物之间表现出最高的相关系数。在快速骨丢失者(其骨丢失超过平均值)和缓慢骨丢失者(其骨丢失低于平均值)中,治疗期间血清雌二醇水平同样受到抑制。然而,在治疗24周时,快速骨丢失者的骨吸收标志物z评分显著更高,但骨形成标志物的z评分则不然,这表明该组骨吸收加速。治疗24周时,z评分最高的三项标志物依次为CTX、NTX和Dpyr,而快速骨丢失者中CTX的z评分最高(P<0.05)。在治疗24周时,CTX处于最高四分位数、NTX处于最高和第二高四分位数的受试者,其骨丢失分别是处于最低四分位数受试者的2.1倍、2.2倍和1.7倍(P<0.001)。此外,CTX和NTX均处于最高四分位数的受试者,其骨丢失是两种标志物均处于最低四分位数受试者的3.6倍(P<0.001)。这些结果表明,CTX和NTX都是GnRHa诱导的低雌激素状态下骨吸收的有用且敏感的标志物。